POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL

J.F. Merola(The University of Texas Southwestern Medical Center), V.P. Werth(University of Pennsylvania), Brandon Becker(Bristol-Myers Squibb (United States)), C. Aranow(Feinstein Institute for Medical Research), Cristina Arriens(Oklahoma Medical Research Foundation), Bankole A. Johnson(Indiana University Bloomington), Nikolay Delev(Bristol-Myers Squibb (Sweden)), François Chasset(Sorbonne Université), Anna Luisa Kühn(University of Massachusetts Chan Medical School), David Fiorentino(Stanford University), A.B. Gottlieb(Icahn School of Medicine at Mount Sinai), Coburn Hobar(Bristol-Myers Squibb (United States)), Shimon Korish(Bristol-Myers Squibb (United States)), Renu Agrawal(Bristol-Myers Squibb (United States)), Beng H. Chong(The University of Texas Southwestern Medical Center), Jürgen J. Wenzel(Institute of Medical Microbiology and Hygiene), Jiyoon Choi(Bristol-Myers Squibb (United States)), Richard Meier(Bristol-Myers Squibb (United States)), Thomas Lehman(Hospital for Special Surgery), Ronald van Vollenhoven(Amsterdam University Medical Centers)
Annals of the Rheumatic Diseases
June 1, 2025
Cited by 5


Related Papers